Liquidia Will Continue To Advance YUTREPIA And L606 Clinical Programs As Previously Outlined; Liquidia Has Submitted A Supplement To Remove The PH-ILD Indication From YUTREPIA’ ’s Label And No Longer Promotes It For PH-ILD

뉴스 본문을 불러오고 있어요.

Liquidia Will Continue To Advance YUTREPIA And L606 Clinical Programs As Previously Outlined; Liquidia Has Submitted A Supplement To Remove The PH-ILD Indication From YUTREPIA’ ’s Label And No Longer Promotes It For PH-ILD | 웨이프 WAPE

Liquidia Will Continue To Advance YUTREPIA And L606 Clinical Programs As Previously Outlined; Liquidia Has Submitted A Supplement To Remove The PH-ILD Indication From YUTREPIA’ ’s Label And No Longer Promotes It For PH-ILD

기사 요약

관련 종목

댓글 —